

Catalyst Pharmaceuticals, Inc. Investor Relations Department 355 Alhambra Circle Suite 1250 Coral Gables, FL 33134 United States

Visit IR website ☐ Sign-up for email alerts ☐ ☐

NASDAQ: CPRX 1 Last Trade: 2.75 Trade Time: 4:00 PM ET 10/23/17 -0.01 Change: (0.362%)Day Range 2.64 - 2.80 52-Week Range 0.94 - 3.20Volume 882,110 Market Cap. 232.540 (\$M) Shares Out (M) 84.560

Company Profile

Catalyst Pharmaceuticals, Inc., is a biopharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder. Catalyst's lead candidate, amifampridine phosphate, for the treatment of LEMS has completed testing in a global, multi-center, double-blinded randomized pivotal Phase 3 trial resulting in positive top-line data. Catalyst has recently filed an NDA for this product seeking approval for its use as a treatment of LEMS and Congenital Myasthenic Syndromes (CMS). Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP-115 by Catalyst) to treat infantile spasms and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder, Tourette's disorder, and movement disorders associated with the treatment of Parkinson's Disease.

... (more)

Stock Performance



Press Releases [View all]

10/16/17

<u>Catalyst Pharmaceuticals to Present at 16th</u> Annual BIO Investor Forum

08/30/17

Catalyst Pharmaceuticals Provides Update on the Status of its Firdapse Development Activities

08/09/17

Catalyst Pharmaceuticals Announces
Second Quarter 2017 Financial Results and
Provides Corporate Update

08/01/17

Catalyst Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10th, 2017

06/26/17

Catalyst Pharmaceuticals Joins Russell 3000 Index

Events [View all]

There are no events to display at this time. Please check back later.

Financials [View all]

03/15/17

Annual Report (10-K)

04/14/17

Definitive Proxy Statement

08/09/17

Quarterly Report (10-Q)

05/10/17

Quarterly Report (10-Q)

11/09/16

Quarterly Report (10-Q)



¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.